Medical Doctor Program year 2024 Reported 2019–2024 Source: CMS Open Payments, 2026 publication

Madhavi Kamireddi

Psychiatry Acton, MA Medical Doctor

NPI 1255313466 CMS profile 854077

289 Great Road, Suite G1, Acton, MA 01720

Open in the dashboard

General payments

$33,098

106 records reported · program years 2019–2024

Research payments

$0

Paid to them · None reported · program years 2019–2024

Ownership & investment interest

$0

None reported

Through program year 2024, Madhavi Kamireddi of Acton, MA is reported in the CMS Open Payments database as having received $33,098 across 106 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 96th percentile of Psychiatry profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

5 rows
Year Kind Relative to this record's peak year Amount Records
2024 General $981 14
2023 General $43 2
2021 General $23,104 28
2020 General $54 3
2019 General $8,915 59

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Madhavi Kamireddi
  • Psychiatry median
  • Middle half of Psychiatry
  • National median

In program year 2025, general payments to Madhavi Kamireddi were reported at $0. Among 14,155 Psychiatry profiles paid that year, the median was $180 and the middle half received between $58 and $685.

Show as a table
Year Madhavi Kamireddi Psychiatry median Middle half National median
2019 $8,915 $184 $59–$605 $163
2020 $54 $119 $36–$372 $114
2021 $23,104 $143 $43–$576 $132
2022 $0 $153 $50–$590 $149
2023 $43 $170 $56–$651 $160
2024 $981 $179 $57–$673 $164
2025 $0 $180 $58–$685 $169

Breakdown

Who paid General payments · program years 2019–2024
  1. Supernus Pharmaceuticals, Inc. $23,104 28 payments
  2. Ironshore Pharmaceuticals Inc. $8,364 26 payments
  3. Janssen Pharmaceuticals, Inc $906 11 payments
  4. Otsuka America Pharmaceutical, Inc. $242 12 payments
  5. Sunovion Pharmaceuticals Inc. $109 9 payments
  6. Tris Pharma Inc $97 6 payments
  7. Neurocrine Biosciences, Inc. $73 4 payments
  8. Takeda Pharmaceuticals U.S.A., Inc. $45 2 payments
  9. Lundbeck LLC $43 2 payments
  10. Shire North American Group Inc $43 2 payments
  11. Other $72 4 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2024
  1. Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program $20,920 14 payments
  2. Travel and Lodging $6,188 22 payments
  3. Consulting Fee $4,000 1 payment
  4. Food and Beverage $1,990 69 payments
Products named General payments · program years 2019–2024
  1. QELBREE $20,010 23 payments
  2. Jornay PM 20mg capsules (Bottle of 100) $8,343 25 payments
  3. SPRAVATO $906 11 payments
  4. LATUDA $109 9 payments
  5. Dyanavel XR $97 6 payments
  6. REXULTI $90 4 payments
  7. ABILIFY MAINTENA $87 5 payments
  8. ABILIFY MYCITE $65 3 payments
  9. INGREZZA $50 3 payments
  10. Trintellix $45 2 payments
  11. Other $273 15 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 6 drugs

Part D claims

103

Median for Psychiatry: 574

Drug cost

$6,767

Median for Psychiatry: $27,624

Branded share of claims

66%

Median for Psychiatry: 17%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Fetzima Levomilnacipran Hcl Brand 11 $5,427
Bupropion Xl Bupropion Hcl Brand 23 $576
Trazodone Hcl Generic 17 $361
Quetiapine Fumarate Er Quetiapine Fumarate Brand 13 $236
Citalopram Hbr Citalopram Hydrobromide Brand 21 $123
Lamotrigine Generic 18 $44

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 20,488 Part D prescribers listed as Psychiatry; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 10 billing codes

Paid by Medicare

$184,547

Medicare's payments for the services billed

Medicare patients

37

Average age 60

Services billed

658

26 women, 11 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
Depression 75%
High blood pressure 46%
Arthritis 43%

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

3 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
SPRAVATO
  • Janssen Pharmaceuticals, Inc $906
$906 — —
REXULTI
  • Otsuka America Pharmaceutical, Inc. $25
  • Lundbeck LLC $22
$47 — —
ABILIFY MYCITE
  • Otsuka America Pharmaceutical, Inc. $28
$28 — —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

Records

106 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Psychiatry in Massachusetts

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2024

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record